about
A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationA therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationFresh frozen plasma for cardiovascular surgeryCytomegalovirus in pregnancy: to screen or not to screen.Emerging Infectious Diseases and Blood Safety: Modeling the Transfusion-Transmission Risk.Myeloma in the Real World: What Is Really Happening?Haemoglobin disorders in Australia: where are we now and where will we be in the future?Evaluation of clinical coding data to determine causes of critical bleeding in patients receiving massive transfusion: a bi-national, multicentre, cross-sectional study.A review of pathophysiology and current treatment for neonatal alloimmune thrombocytopenia (NAIT) and introducing the Australian NAIT registry.A no-prophylaxis platelet-transfusion strategy for hematologic cancers.Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis.Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: findings from the first 5 years of the Australian TTP/thrombotic microangiopathy registry.Platelet Transfusions in Patients with Hypoproliferative Thrombocytopenia: Conclusions from Clinical Trials and Current Controversies.Contemporary management of neonatal alloimmune thrombocytopenia: good outcomes in the intravenous immunoglobulin era: results from the Australian neonatal alloimmune thrombocytopenia registry.Hospital blood bank information systems accurately reflect patient transfusion: results of a validation study.Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study.Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors.Age of red blood cells and mortality in the critically ill.Transfusion interventions in critical bleeding requiring massive transfusion: a systematic review.Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron)Improving outcomes for hospital patients with critical bleeding requiring massive transfusion: the Australian and New Zealand Massive Transfusion Registry study methodology.Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.A review on decision support for massive transfusion: understanding human factors to support the implementation of complex interventions in trauma.The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions.Transfusing blood safely and appropriately.Bacterial safety of cell-based therapeutic preparations, focusing on haematopoietic progenitor cells.Wrong blood in tube - potential for serious outcomes: can it be prevented?The evolving role of the transfusion practitioner.Intravenous immunoglobulin in critically ill adults: When and what is the evidence?An international investigation into O red blood cell unit administration in hospitals: the GRoup O Utilization Patterns (GROUP) study.Optimal Dose, Timing and Ratio of Blood Products in Massive Transfusion: Results from a Systematic Review.Bacterial Pre-Release Testing of Platelets - the Australian Red Cross Blood Service Clinical Experience.Anemia and iron-restricted erythropoiesis in traumatic critical illness.Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials.Fibrinogen is an independent predictor of mortality in major trauma patients: A five-year statewide cohort study.Descriptive characteristics and in-hospital mortality of critically bleeding patients requiring massive transfusion: results from the Australian and New Zealand Massive Transfusion Registry.Bronchial thermoplasty in severe asthma in Australia.The International Haemovigilance Network Database for the Surveillance of Adverse Reactions and Events in Donors and Recipients of Blood Components: technical issues and results.Profiling clinical platelet and plasma use to inform blood supply and contingency planning: PUPPY, the prospective utilization of platelets and plasma study.Hemoglobin and iron indices in nonanemic premenopausal blood donors predict future deferral from whole blood donation.
P50
Q24186913-D60A373B-3E01-4182-8A28-74C04C59BE92Q24198288-C3024A8C-FD30-41A9-8DC3-517DF8478332Q24242528-E69740E1-ABFB-4A51-8910-A7B80992001BQ26851794-A3F48AD1-02DB-4E7D-A4C6-EB3C3C254D6AQ30145555-79182386-E802-415F-B42D-797F848A132BQ30238637-33A688B1-470B-4E33-AB0C-89077888B492Q30251663-D6D1959F-CF2E-4989-BCC5-120F0FAA2585Q31148693-DE01B9DC-B8C2-41F2-9CEB-AE98BF13D576Q33395614-40EE1C67-5919-4AC2-8293-BFA1EF193C9FQ33407550-986D7FB9-D75C-490B-A59A-C5803B37BB0CQ33421355-96FBC883-EE60-44BD-A01F-323352B6BC2BQ33426823-4A48D321-13E4-4D93-95D9-6F365E4F5010Q33431739-2470D562-9063-4824-A415-9E53AA003AE6Q33436491-6F60AF7E-92A2-4904-BD8C-A741D27EDB92Q33453241-C117B163-A641-48BC-8CA9-24679AA7CE5AQ35124447-763EE514-B0C6-46C6-9798-FD93987B6489Q35143453-EC2DAA5D-F43B-43CF-BD9C-52F63438BB23Q35559622-4EBC7DB4-5652-404B-BC13-81FB7482E7C8Q35567905-00653FEB-E237-4DE5-8CFE-98F6C104E999Q35960098-7ACE5375-1DD0-4364-985A-5217F3D411C5Q36157370-A7F5BB87-3963-4A1E-99EB-3B31411257BBQ36187791-C8DB1CC8-AC52-454C-BFFC-F93CB2A655D9Q38002418-D28CAB45-A92B-4A57-840F-68C08385750BQ38073018-3BB4312D-B0B6-4ECE-861F-2F277347FD85Q38122130-0278FC57-B7EA-4A3B-8730-BBC29F90E21FQ38201748-BBC29E09-6B94-4FA3-8CCA-B00576FCE381Q38256871-DEE31584-9F92-4BDD-952E-9E9F37E9A0E6Q38337075-69F66DBB-3706-46FD-A737-F3DF7365FFDEQ38363642-A8C95DD1-84C5-4661-93DD-CBA8190B3A5BQ38398843-8BC1F999-AA2E-4B0C-B4C2-8D9EB689C83BQ38627144-2D4B115A-81C0-4ECD-B246-6665C613A1BAQ38667326-4D19DE8D-DCFE-4A79-AE6B-C898AF4367CAQ38670055-3DE7518A-2A04-4500-942D-0AF50F2F0F9AQ38674818-6CDFAD06-C1CF-4A8F-B249-552628167250Q38758388-5CCBC28B-9AC1-4932-8132-629A54ED279BQ38970468-B6252085-6DAE-4422-AF7E-1DCF710D9DB4Q39013192-18BA2B97-8866-4436-AC23-8DDD010099EEQ39362079-D424BF2F-97A5-4D96-BE30-E0DFE1321E88Q39417906-2A026FA1-74A4-4F82-8FC6-663D7F53D492Q39749875-62F7A149-8B76-4B0A-8CA4-700F95B3907D
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Erica M. Wood
@ast
Erica M. Wood
@en
Erica M. Wood
@es
Erica M. Wood
@nl
Erica M. Wood
@sl
type
label
Erica M. Wood
@ast
Erica M. Wood
@en
Erica M. Wood
@es
Erica M. Wood
@nl
Erica M. Wood
@sl
prefLabel
Erica M. Wood
@ast
Erica M. Wood
@en
Erica M. Wood
@es
Erica M. Wood
@nl
Erica M. Wood
@sl
P106
P1153
7403120470
P21
P31
P496
0000-0001-7527-2340